Home Newsfeeds JP Morgan Maintains Neutral on Werner Enterprises, Raises Price Target to $39

JP Morgan Maintains Neutral on Werner Enterprises, Raises Price Target to $39

JP Morgan analyst Brian Ossenbeck maintains Werner Enterprises (NASDAQ:WERN) with a Neutral and raises the price target from $38 to $39.

byBenzinga Newsdesk

February 8, 2023

1 minute read

JP Morgan analyst Brian Ossenbeck maintains Werner Enterprises (NASDAQ:WERN) with a Neutral and raises the price target from $38 to $39.

News

L3Harris Emergency Responder Radio Solution Receives NFPA Certification

By Benzinga Newsdesk

December 14, 10:32 AM

Meets or exceeds all NFPA certification requirements for devices operating in extreme environments Validates devices can withstand extreme conditions, including heat, emersion and shock Assures critical connectivity

LHX

WidePoint Sees FY23 Revenue $106M Vs $104.16M Est.; Building Upon A Robust Q4, Sustains Momentum With A Substantial Federal Contract Backlog Totaling $359M As Of December 31, 2023

By Benzinga Newsdesk

February 13, 10:49 AM

WidePoint Corporation (NYSE:WYY), the innovative technology Managed Solution Provider (MSP) specializing in Identity & Access Management (IAM), Telecommunications and Managed Mobility Services (MMS), Analytics &

WYY

Why DexCom Shares Are Trading Higher Today

By Lekha Gupta

July 28, 10:01 AM

DexCom Inc (NASDAQ: DXCM) shares are trading higher after the company reported

DXCM

Events
News

Centessa Pharmaceuticals Announced New Data From Additional 52-Weeks of Continuous Treatment From Third Year (Part 5) Of Ongoing Phase 2a Study Of SerpinPC For Treatment Of Hemophilia At 2023 ASH Meeting

By Charles Gross

December 10, 1:57 PM

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of

CNTA

JP Morgan Maintains Neutral on Werner Enterprises, Raises Price Target to $39

Related Posts

L3Harris Emergency Responder Radio Solution Receives NFPA Certification

WidePoint Sees FY23 Revenue $106M Vs $104.16M Est.; Building Upon A Robust Q4, Sustains Momentum With A Substantial Federal Contract Backlog Totaling $359M As Of December 31, 2023

Why DexCom Shares Are Trading Higher Today

Centessa Pharmaceuticals Announced New Data From Additional 52-Weeks of Continuous Treatment From Third Year (Part 5) Of Ongoing Phase 2a Study Of SerpinPC For Treatment Of Hemophilia At 2023 ASH Meeting